Clinical Trials Logo

Hemorrhage clinical trials

View clinical trials related to Hemorrhage.

Filter by:

NCT ID: NCT03706768 Recruiting - Clinical trials for Aneurysmal Subarachnoid Hemorrhage

Degradation of the Glycocalyx in Delayed Cerebral Ischemia After Aneurysmal Subarachnoid Hemorrhage

Start date: May 1, 2018
Phase: N/A
Study type: Interventional

This study will provide novel information to the literature base for the pathophysiology of aneurysmal subarachnoid hemorrhage. The association of breakdown products in the serum of aSAH patients were reported in a very small case series of 3 patients, as mentioned above. However, while their results are intriguing and encouraging, our study will provide more definitive information about the GC in aSAH. If there is a positive correlation, the results of this study will guide future investigations into new therapies for this devastating disease such as MMP inhibition with doxycycline.

NCT ID: NCT03706339 Completed - Clinical trials for Cesarean Section Complications

Reducing Blood Loss During Cesarean Section by Topical Versus IV Tranexamic Acid

Start date: November 1, 2018
Phase: N/A
Study type: Interventional

Tranexamic (TXA)acid is an inexpensive, antifibrinolytic drug long used to control bleeding due to surgery, menorrhagia, or trauma. Additionally, tranexamic acid has been shown to reduce bleeding during cesarean delivery as well as the need for additional uterotonic agents, albeit to a minimal degree. However, previous studies have been performed only in women with a standard risk for postpartum hemorrhage( PPH) and have not focused on assessing the effects of tranexamic acid in high‐risk women. The aim of this study is to evaluate the efficacy of IV versus topical application of tranexamic acid in reducing blood loss during and after elective C.S. The Research Question Is topical application of Tranexamic acid effective in reducing blood loss during and after an elective Caesarean section? The Research Hypothesis the TXA could be able to reduce blood loss during and after elective Caesarean section. The null hypothesis will, therefore, state that: There will be no difference between topical and IV TXA and placebo in reducing blood loss during and after elective Caesarean section.

NCT ID: NCT03705247 Completed - Bleeding Clinical Trials

The Role of Bleeding at Implant Placement

Start date: October 1, 2018
Phase:
Study type: Observational

Angiogenesis is inherently associated to bone formation and healing. During implant osseointegration, a successive and successful angiogenic processes has to occur to promote bone formation. In 1969, Branemark et al. demonstrated that direct contact between bone and titanium implant surface was possible, defining osseointegration as "the direct, structural, and functional contact between live bone and the surface of a functionally loaded implant". Consequently, the need of an empirical measurement appeared. With the introduction of resonance frequency analysis (RFA), it is now possible to measure the degree of implant stability at any time during the course of implant treatment and loading. In this way, changes in implant stability can be monitored over the time and it is likely possible to find implants at risk of failure before they become loose. The rationale of this study is to analyse how important a good vascularization is for the future bone formation around dental implants.

NCT ID: NCT03703323 Terminated - Hemorrhage Clinical Trials

Comparison of Mortality Impact of Coagulation Rotative Thromboelastometry Analysis Versus Standard Analysis

HD-ROTEM
Start date: October 8, 2018
Phase: N/A
Study type: Interventional

Digestive hemorrhage is a common cause of acute hemorrhage in France, and its mortality remains high despite improvement of endoscopy technique and therapeutics. Hemostasis disorders are an important issue in the patient care both in severity diagnostic and therapeutic plan.

NCT ID: NCT03702582 Completed - Stroke Clinical Trials

Rivaroxaban vs. Warfarin for Post Cardiac Surgery Atrial Fibrillation

NEW-AF
Start date: April 30, 2019
Phase: Phase 3
Study type: Interventional

This prospective, randomized, active-controlled, parallel arm study compares the safety and financial benefits of arterial thromboembolism prophylaxis with Warfarin vs. Rivaroxaban (A novel oral anticoagulant) in patients with new onset atrial fibrillation after sternotomy for cardiac operations.

NCT ID: NCT03700853 Completed - Clinical trials for Dysphagia Following Cerebral Infarction

Validation and Reliability Testing of Dysphagia Trained Nurse Assessment

Start date: December 1, 2017
Phase:
Study type: Observational

Nurses at Royal Derby Hospital, UK have been trained to use a comprehensive protocol based dysphagia assessment (Dysphagia Trained Nurse Assessment (DTNAx)) to assess all acute stroke patients on admission. This study aims to validate the tool by comparing it to the gold standard assessment - Videofluoroscopy and usual assessment by a Speech and Language Therapist. Inter-rater and intra-rater reliability will also be tested by comparing the assessment results of two different nurses or the same nurse.

NCT ID: NCT03699618 Terminated - Clinical trials for Neovascular Age-related Macular Degeneration

Anti-VEGF Therapy for Subfoveal Hemorrhage in Patients With Neovascular Age-Related Macular Degeneration

Start date: May 29, 2019
Phase:
Study type: Observational

This study will define the limits of subretinal hemorrhage parameters that are consistent with a good visual outcome with aggressive anti-VEGF treatment in patients with neovascular age-related macular degeneration (NVAMD).

NCT ID: NCT03696121 Completed - Stroke, Acute Clinical Trials

Desmopressin for Reversal of Antiplatelet Drugs in Stroke Due to Haemorrhage

DASH
Start date: April 1, 2019
Phase: Phase 2
Study type: Interventional

Haemorrhagic stroke, an emergency caused by bleeding in the brain, often leads to death or long-term disability. A quarter of these patients are taking blood-thinning drugs (antiplatelet drugs, such as aspirin) because they are at risk of a heart attack or ischaemic stroke. Patients taking these drugs are more likely to die or be disabled if they have a haemorrhagic stroke. At present, there is no effective treatment for reversing their effects. Desmopressin is a drug which may reverse the effects of antiplatelet drugs and stop bleeding. The investigators would like to run a large randomised trial to see if Desmopressin can reduce the number of people who die or are disabled after haemorrhagic stroke.

NCT ID: NCT03693599 Completed - Clinical trials for Post Partum Hemorrhage

Carbetocin Versus Syntometrine in Obese Women Undergoing Elective Cesarean

Start date: October 1, 2018
Phase: Phase 4
Study type: Interventional

to compare effectiveness and tolerability of carbetocin versus syntometrine in prevention of Postpartum hemorrhage after cesarean section

NCT ID: NCT03691727 Completed - Clinical trials for Subarachnoid Hemorrhage, Aneurysmal

Induced Suppression of Platelets Activity in Aneurysmal SAH Management (iSPASM)

Start date: January 24, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

This is a phase 1/2a, randomized, double blind, single-center study comparing standard care alone to standard care with Aggrastat in patients diagnosed with aneurysmal subarachnoid hemorrhage.